ClinicalTrials.gg

Program

oleclumab

Also written as “Oleclumab”, “Durvalumab + Oleclumab” and “E2 - mFOLFOX6, durvalumab and oleclumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma · Colonic Neoplasms, led by AstraZeneca.

Furthest: phase 3, since Jan 14, 20228 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca84 open or runningphase 3since Jan 14, 2022Sep 22, 2017Jan 8, 2027phase 3 · NCT05221840
  • Named in AstraZeneca’s own pipeline as oleclumab, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03334617 · 528 enrolled · United States, Austria, Canada and more
  2. May 18, 2018Phase 2 study in CarcinomaNCT03611556 · 213 enrolled · United States, Australia, Norway and more
  3. Nov 7, 2018Phase 1 study in Advanced Solid MalignanciesNCT03736473 · 6 enrolled · Japan
  4. Dec 10, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03822351 · 189 enrolled · United States, Canada, France and more
  5. Oct 16, 2019Phase 2 study in Colonic NeoplasmsNCT04145193
  6. Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
  7. Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
  8. Sep 18, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06606847 · 30 enrolled · Russia
  9. Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840

Ahead

  1. Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840
  2. May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550

TargetBeta

“A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. Th…”NCIt, read by Claude

Other programs on NT5E

ProgramCompanyFurthest phaseStudies
quemliclustatruleArcus Biosciencesphase 37
uliledlimabruletj-biopharma-co-ltdphase 34

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06606847Carcinoma, Non-Small-Cell Lung · Russia2Active, not recruitingMay 4, 202630
NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingJan 8, 20271,051
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingMay 28, 2030630
NCT04145193Colonic Neoplasms2WithdrawnMar 19, 20240
NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedJul 18, 2023189
NCT03736473Advanced Solid Malignancies · Japan1CompletedJun 19, 20196
NCT03611556Carcinoma · United States, Australia, Norway and more2CompletedJul 22, 2022213
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingSep 13, 2024528

How it is read

Names in the registry

  • “Oleclumab”, 5 entries
  • “Durvalumab + Oleclumab”, 1 entry
  • “E2 - mFOLFOX6, durvalumab and oleclumab”, 1 entry
  • “MEDI9447 (oleclumab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.